Heterogeneous distribution of PD-L1 expression in the IASLC/ATS/ERS classification of lung adenocarcinoma

• Published in: International journal of clinical oncology 2022, Vol.27 (1), p.105-111
• Main Authors: Zhang, Dachuan, Gao, Xie, Yan, Zhantao, He, Wenting, Li, Qing
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Adenocarcinoma of Lung - genetics; Adenocarcinoma of Lung - pathology; B7-H1 Antigen - genetics; Cancer; Cancer Research; Humans; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Lymph nodes; Medicine; Medicine & Public Health; Metastases; Neoplasm Staging; Oncology; Original Article; PD-1 protein; PD-L1 protein; Prognosis; Smoking; Surgical Oncology; Tumor cells
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-021-02035-2

Background PD-L1 expression in tumor cells can predict the efficacy of PD-1/PD-L1 inhibitors and prognosis in patients. However, the correlation between the PD-L1 expression and the novel lung adenocarcinoma classification are obscure. Methods 94 lung adenocarcinoma cases were reviewed in the Third Affiliated Hospital of Soochow University from January to December 2019. PD-L1 (DAKO 22C3) was used to test the PD-L1 expression in lung cancer tissue. Result TPS was used to interpret the PD-L1 expression. The negative, low positive and high positive of PD-L1 were 52 cases (55.30%), 29 cases (30.90%) and 13 cases (13.80%). The subtype ratio of acinar, lepidic and solid in adenocarcinoma were correlation with the PD-L1 TPS ( r  =  − 0.37, P